BR112017024328A2 - métodos de tratamento usando nanopartículas ultrapequenas para induzir morte celular de células cancerosas privadas de nutrientes via ferroptose - Google Patents

métodos de tratamento usando nanopartículas ultrapequenas para induzir morte celular de células cancerosas privadas de nutrientes via ferroptose

Info

Publication number
BR112017024328A2
BR112017024328A2 BR112017024328A BR112017024328A BR112017024328A2 BR 112017024328 A2 BR112017024328 A2 BR 112017024328A2 BR 112017024328 A BR112017024328 A BR 112017024328A BR 112017024328 A BR112017024328 A BR 112017024328A BR 112017024328 A2 BR112017024328 A2 BR 112017024328A2
Authority
BR
Brazil
Prior art keywords
cell death
ultra
ferroptosis
induce cell
cancer cells
Prior art date
Application number
BR112017024328A
Other languages
English (en)
Portuguese (pt)
Inventor
Scher Howard
Ma Kai
Overholtzer Michael
S Bradbury Michelle
Wiesner Ulrich
Original Assignee
Univ Cornell
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell, Memorial Sloan Kettering Cancer Center filed Critical Univ Cornell
Publication of BR112017024328A2 publication Critical patent/BR112017024328A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ceramic Engineering (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112017024328A 2015-05-29 2016-05-26 métodos de tratamento usando nanopartículas ultrapequenas para induzir morte celular de células cancerosas privadas de nutrientes via ferroptose BR112017024328A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168636P 2015-05-29 2015-05-29
US201662280960P 2016-01-20 2016-01-20
PCT/US2016/034351 WO2016196201A1 (en) 2015-05-29 2016-05-26 Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis

Publications (1)

Publication Number Publication Date
BR112017024328A2 true BR112017024328A2 (pt) 2018-07-24

Family

ID=56134596

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017024328A BR112017024328A2 (pt) 2015-05-29 2016-05-26 métodos de tratamento usando nanopartículas ultrapequenas para induzir morte celular de células cancerosas privadas de nutrientes via ferroptose

Country Status (10)

Country Link
US (3) US10736972B2 (https=)
EP (1) EP3302568B1 (https=)
JP (2) JP6974178B2 (https=)
KR (1) KR102730833B1 (https=)
CN (2) CN108377643B (https=)
AU (1) AU2016271040A1 (https=)
BR (1) BR112017024328A2 (https=)
CA (1) CA2985126A1 (https=)
HK (1) HK1253536A1 (https=)
WO (1) WO2016196201A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
DK3223013T3 (en) 2009-07-02 2019-04-15 Sloan Kettering Inst Cancer Res FLUORESCING SILICA-BASED NANOPARTICLES
CA2900363C (en) 2013-03-15 2023-10-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
EP3148591B1 (en) 2014-05-29 2020-03-11 Memorial Sloan Kettering Cancer Center Nanoparticle drug conjugates
US10736972B2 (en) 2015-05-29 2020-08-11 Memorial Sloan Kettering Cancer Center Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
WO2017189961A1 (en) 2016-04-29 2017-11-02 Memorial Sloan Kettering Cancer Center Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
EP3630089A4 (en) * 2017-05-24 2021-06-09 Ferro Therapeutics, Inc. PROCEDURE FOR CANCER THERAPY
WO2018217528A1 (en) * 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof
EP3645739A4 (en) * 2017-06-28 2021-07-14 The Regents of the University of California METHODS AND COMPOSITIONS FOR TREATMENT OF MELANOMA
US20200383943A1 (en) * 2017-12-04 2020-12-10 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis
US20210074995A1 (en) 2018-01-31 2021-03-11 Lg Chem, Ltd. Negative electrode active material, negative electrode including the same and lithium secondary battery including the same
JP7348906B2 (ja) 2018-02-28 2023-09-21 フェロ セラピューティクス， インコーポレイテッド フェロトーシス誘導活性を有する化合物およびそれらの使用方法
WO2019200343A1 (en) * 2018-04-13 2019-10-17 The Wistar Institute Of Anatomy And Biology S6k2 blockade perturbs redox balance and fatty acid metabolism, leading to oxidative cell death in mapk inhibitor resistant cancers
US12268742B2 (en) 2018-05-02 2025-04-08 Memorial Sloan Kettering Cancer Center Nanotherapeutic systems and methods using particle-driven photodynamic therapy (PDT)
WO2020077361A1 (en) * 2018-10-12 2020-04-16 The General Hospital Corporation Compounds and methods of their use
US12201956B2 (en) 2018-10-16 2025-01-21 Pharma In Silica Laboratories Inc. Tunable process for silica capsules/spheres preparation and their use
US20220193275A1 (en) * 2018-12-17 2022-06-23 Memorial Sloan Kettering Cancer Center Inducing favorable effects on tumor microenvironment via administration of nanoparticle compositions
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
WO2022093800A2 (en) 2020-10-27 2022-05-05 Elucida Oncology, Inc. Carrier particle-drug conjugates, self-immolative linkers, and uses thereof
CN112274495B (zh) * 2020-10-31 2022-05-03 郑州大学 一种h2o2自供型过氧化钙负载姜黄素纳米粒的制备方法及其应用
US20240285543A1 (en) * 2021-06-21 2024-08-29 Memorial Sloan-Kettering Cancer Center Nanoparticle-mediated enhancement of immunotherapy to promote ferroptosis-induced cytotoxicity and antitumor immune responses
WO2023023288A1 (en) * 2021-08-19 2023-02-23 Arpeggio Biosciences, Inc. Small molecule modulators of ferroptosis
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
CN115120595B (zh) * 2022-08-02 2023-06-30 广西医科大学第一附属医院 Liproxstatin-1在制备防治白血病的药物中的应用和其药物组合物
CN116270624A (zh) * 2023-02-14 2023-06-23 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Tubastatin A的新应用
WO2025198008A1 (ja) * 2024-03-22 2025-09-25 公益財団法人がん研究会 フェロトーシス誘導促進剤
CN118879871B (zh) * 2024-09-27 2025-05-30 中国人民解放军总医院第三医学中心 一种肾癌预后标志物tymp及tymp抑制剂的应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870791A (en) 1972-04-24 1975-03-11 Heskel M Haddad Solid state ophthalmic medication delivery method
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4136177A (en) 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4255415A (en) 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4688506A (en) 1985-09-03 1987-08-25 Breems Martinus Van Boat sail control system
US4788603A (en) 1985-10-19 1988-11-29 Fuji Photo Film Co., Ltd. Camera for sequentially photographing a subject using a reference optical system and a telescopic optical system
US4812409A (en) 1986-01-31 1989-03-14 Eastman Kodak Company Hydrolyzable fluorescent substrates and analytical determinations using same
US4713224A (en) 1986-03-31 1987-12-15 The Boc Group, Inc. One-step process for purifying an inert gas
US4810636A (en) 1986-12-09 1989-03-07 Miles Inc. Chromogenic acridinone enzyme substrates
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
CA2299471C (en) * 1997-08-15 2007-12-18 Cephalon Inc. Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
GB2330907A (en) 1997-10-28 1999-05-05 Applied Imaging Int Ltd A karyotyper and methods for producing karyotypes
ATE239801T1 (de) 1998-01-22 2003-05-15 Luminex Corp Mikropartikel mit multiplen fluoreszenz-signalen
US6254852B1 (en) 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
WO2003066066A1 (en) 2002-02-01 2003-08-14 Vanderbilt University Targeted drug delivery methods
US8620410B2 (en) 2002-03-12 2013-12-31 Beth Israel Deaconess Medical Center Multi-channel medical imaging system
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
WO2004108902A2 (en) 2003-06-04 2004-12-16 Visen Medical, Inc. Biocompatible fluorescent silicon nanoparticles
WO2006042233A1 (en) 2004-10-08 2006-04-20 The Cleveland Clinic Foundation Medical imaging using quantum dots
US7653427B2 (en) 2004-11-12 2010-01-26 Intra-Medical Imaging LLC Method and instrument for minimally invasive sentinel lymph node location and biopsy
AU2006339072A1 (en) 2005-03-14 2007-10-25 Board Of Regents Of The University Of Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
WO2006099445A2 (en) 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
US8084001B2 (en) 2005-05-02 2011-12-27 Cornell Research Foundation, Inc. Photoluminescent silica-based sensors and methods of use
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
JP2008546804A (ja) 2005-06-24 2008-12-25 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 造影剤として用いるためのリガンドの放射性標識ペグ化
FR2888753B1 (fr) 2005-07-21 2008-04-04 Commissariat Energie Atomique Vecteur cible avec fonction d'imagerie activable
WO2007136413A2 (en) 2005-12-22 2007-11-29 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
WO2008044138A1 (en) 2006-10-12 2008-04-17 Syddansk Universitet Optical nanosensor for detection of reactive oxygen species
WO2008049118A2 (en) 2006-10-19 2008-04-24 The General Hospital Corporation Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample and effecting such portion(s)
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
WO2008073856A2 (en) 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
US8239008B2 (en) 2007-04-13 2012-08-07 Ethicon Endo-Surgery, Inc. Sentinel node identification using fluorescent nanoparticles
EP1995327A1 (en) 2007-05-21 2008-11-26 Humboldt Universität zu Berlin Probe for detecting a particular nucleic acid sequence
WO2009029870A2 (en) 2007-08-31 2009-03-05 Hybrid Silica Technologies, Inc. Peg-coated core-shell silica nanoparticles and methods of manufacture and use
DE102007052517A1 (de) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT-Verfahren mit zwei Filtersystemen
WO2009064964A2 (en) 2007-11-15 2009-05-22 The University Of California Switchable nano-vehicle delivery systems, and methods for making and using them
WO2009085218A1 (en) 2007-12-21 2009-07-09 President And Fellows Of Harvard College Sub-diffraction limit image resolution in three dimensions
WO2010091294A2 (en) 2009-02-05 2010-08-12 The Regents Of The University Of California New targeted antimicrobial moieties
ES2700870T3 (es) 2009-04-15 2019-02-19 Univ Cornell Nanopartículas de sílice fluorescentes mejoradas a través de densificación de sílice
US9005575B2 (en) 2009-06-12 2015-04-14 Stc.Unm Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
DK3223013T3 (en) 2009-07-02 2019-04-15 Sloan Kettering Inst Cancer Res FLUORESCING SILICA-BASED NANOPARTICLES
US9238069B2 (en) * 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
IN2012DN05099A (https=) 2009-12-16 2015-10-09 Brigham & Womens Hospital
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
GB201121288D0 (en) 2011-12-12 2012-01-25 Univ Muenster Wilhelms Functionalised silicon nanoparticles
US9006987B2 (en) 2012-05-07 2015-04-14 Lighting Science Group, Inc. Wall-mountable luminaire and associated systems and methods
US10732115B2 (en) 2012-06-22 2020-08-04 Cornell University Mesoporous oxide nanoparticles and methods of making and using same
US9695133B2 (en) * 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
EP2959299B1 (en) 2013-02-20 2019-01-02 Cornell University Multilayer fluorescent nanoparticles and methods of making and using same
CA2900363C (en) 2013-03-15 2023-10-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
US10986997B2 (en) 2013-12-31 2021-04-27 Memorial Sloan Kettering Cancer Center Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time
EP3148591B1 (en) 2014-05-29 2020-03-11 Memorial Sloan Kettering Cancer Center Nanoparticle drug conjugates
CA2954725A1 (en) 2014-07-25 2016-01-28 Northeastern University Biopolymer-nanoparticle composite implant for tumor cell tracking
EP3029032A1 (en) 2014-12-05 2016-06-08 Centre National de la Recherche Scientifique (CNRS) Bifunctional do2pa derivatives, chelates with metallic cations and use thereof
RU2017122621A (ru) 2014-12-15 2019-01-17 Мемориал Слоун Кеттеринг Кэнсер Сентр Циклические пептиды с улучшенной селективностью связывания с нервами, наночастицы, связанные с указанными циклическими пептидами, и их применение для визуализации нервной ткани in vivo в реальном времени
JP6869187B2 (ja) 2015-04-07 2021-05-12 メモリアル スローン ケタリング キャンサー センター ナノ粒子イムノコンジュゲート
US11291737B2 (en) 2015-05-04 2022-04-05 Cornell University Ultrasmall nanoparticles and methods of making and using same
US10736972B2 (en) 2015-05-29 2020-08-11 Memorial Sloan Kettering Cancer Center Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
US20180296595A1 (en) 2015-09-11 2018-10-18 Memorial Sloan Kettering Cancer Center Methods and compositions for cancer treatment
US11660354B2 (en) 2016-11-30 2023-05-30 Memorial Sloan Kettering Cancer Center Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
WO2018191316A1 (en) 2017-04-10 2018-10-18 Cornell University Sulfur- or heavy atom-containing nanoparticles, methods of making same, and uses thereof
JP7309198B2 (ja) 2017-05-19 2023-07-18 コーネル ユニバーシティー 機能性ナノ粒子及びそれを製造する方法並びに使用する方法
EP3630089A4 (en) 2017-05-24 2021-06-09 Ferro Therapeutics, Inc. PROCEDURE FOR CANCER THERAPY
WO2018217528A1 (en) 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof
EP3642599B1 (en) 2017-06-23 2025-01-08 Memorial Sloan-Kettering Cancer Center Method of imaging in vivo tissues using nanoparticles comprising a reference dye and a sensor dye.
US20200383943A1 (en) 2017-12-04 2020-12-10 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis

Also Published As

Publication number Publication date
JP6974178B2 (ja) 2021-12-01
EP3302568A1 (en) 2018-04-11
AU2016271040A1 (en) 2017-11-23
KR102730833B1 (ko) 2024-11-18
US11931425B2 (en) 2024-03-19
CN113559279A (zh) 2021-10-29
JP2018516249A (ja) 2018-06-21
JP7263485B2 (ja) 2023-04-24
WO2016196201A1 (en) 2016-12-08
US20220118106A1 (en) 2022-04-21
CN108377643B (zh) 2021-09-21
CA2985126A1 (en) 2016-12-08
CN108377643A (zh) 2018-08-07
US20200316219A1 (en) 2020-10-08
EP3302568B1 (en) 2023-12-06
HK1253536A1 (zh) 2019-06-21
JP2022023210A (ja) 2022-02-07
US10736972B2 (en) 2020-08-11
US20180169264A1 (en) 2018-06-21
KR20180012299A (ko) 2018-02-05
US11246946B2 (en) 2022-02-15

Similar Documents

Publication Publication Date Title
BR112017024328A2 (pt) métodos de tratamento usando nanopartículas ultrapequenas para induzir morte celular de células cancerosas privadas de nutrientes via ferroptose
PE20150091A1 (es) Anticuerpos anti-sez6 y metodos de empleo
CR20180503A (es) Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos
GB2545584A (en) Acid-soluble cement composition
BR112018011646A2 (pt) atualização de modelo de velocidade com um gradiente de inversão
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
BR112015023020A2 (pt) combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
BR112014031424A2 (pt) tratamento de células pluripotentes
BR112013014003A2 (pt) Métodos de redução de produção de sebo na pele
MX366292B (es) Composiciones biofotónicas que comprenden un cromóforo y un agente gelificante para el tratamiento de heridas.
BR112015021189A2 (pt) métodos de banco de células de alta densidade
MX2015011228A (es) Sales de glicopirrolato.
EP2533788A4 (en) STABLE SOLUTION
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
BR112016018358A2 (pt) Composição reativa, e, processo
MY175346A (en) Methods for acidizing a subterranean formation using a stabilized microemulsion carrier fluid
MY198140A (en) Combination Therapy With Sorafenib or Regorafenib and a Phosphoramidate Prodrug of Troxacitabine
BR112017021193A2 (pt) aquisição melhorada de células para comunicações do tipo máquina melhoradas
MX2015015271A (es) Depuradores de sulfuro a base de azucar reductor y metodos de uso en operaciones subterraneas.
AR107118A1 (es) Método para el control de compuestos formadores de sulfato en la preparación de sulfato de potasio a partir de minerales que contienen potasio a altas temperaturas ambiente
CL2012003052A1 (es) Procedimiento para el empobrecimiento de magnesio y el enriquecimiento de litio en soluciones salinas, que comprende adicionar kcl a la solución que se ha de seguir secando por evaporación, el que se transforma con el mgcl2 de la solución en carnalita potasica y se agrega en forma de carnalita potasica.
PL405540A1 (pl) Sposób otrzymywania ksantohumolu
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112014029308A2 (pt) um método de melhorar a função hepática
MX382936B (es) Liberación de protones de nitrobenzaldehído para la manipulación de la acidosis celular.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements